Ultimate Stock Tips

A Review of Quarter Reports (KLSE Stocks on My Watchlist 2023) - v2

Publish date: Sun, 18 Jun 2023, 11:13 PM
Unique content created once in a blue moon to increase the quality of articles of klse.i3investor.com. (used to be weekly)


For 31 Mac 2023 quarter, AHEALTH had a 50%+ increase in net profit YOY. 

As usual, AHEALTH possessed a strong cash hoard with little borrowing. Net cash from operations remained strong.

After the bonus issues were allocated, share price dipped a bit. However, my confidence in AHEALTH is unswayed.

No problems for me to hold until the next year.


Share price rose quite a lot since my last QR update. But, the recent QR is not encouraging. Should the oversupply situation persists for the next 6 months, HARTA's share price is sure to fall again.

Luckily, the management was wise to conserve the excess cash, which can be used to withstand the incredibly tough times now. 

Glove companies are not out of the woods yet, so for me, a lot of waiting is required. 


Recent QR in May should be the main reason for its share price decline. Management was very honest and informed the public that it expects "the operating environment to be challenging and our financial performance to be flat with downside bias during Q4 FY2023". A substantial RM1bil+ of short term debts was cleared off, which I think is prudent if interest rates continue increasing.

IMO, IOICORP is still a well-managed company worth holding for the long term. Being a KLCI component stock, when foreign funds return to Malaysian stock market, IOICORP should rise in tandem. Although it's almost impossible for CPO prices to reach last year's heights in the next 6 months, the El Nino phenomenon is expected to lift CPO prices. IOICORP is also involved in both upstream & downstream, which is less susceptible to volatile CPO prices. 


My initial case for CDB is the same as IOICORP, as both are heavyweight KLCI companies which are also regular dividend payers. Celcom and DIgi are also household names that command a significant portion of telco consumers in Malaysia. The worry for CDB is the saturated Malaysian market with low growth and possibly huge capex for 5G, which may reduce dividends.  

Those who haven't bought CDB, might find it more useful to stay on the sidelines first, to see whether the merger generates the desired economies of scale between Celcom-DIgi.


Good business as usual for Heineken Malaysia as social activities resume without hindrance of Covid-19 curbs but share price is expected to move sideways as the state elections draw nearer.


It's always darkest before dawn. I won't give up and soldier on. 

Disclaimer: This article is not tailored financial advice, but mere general stock sharing / observations. Please do further due diligence. The author disclaims all liabilities from readers. The author may own some abovementioned stocks.

Be the first to like this. Showing 0 of 0 comments

Post a Comment